Table 2.
Distribution of levels of selenium species and β-amyloid, t-tau, and p-tau at baseline in cerebrospinal fluid of the study population according to diagnosis at the end of follow-up
| MCI (N = 29) | AD (N = 21) | FTD (N = 4) | LBD (N = 2) | |||
|---|---|---|---|---|---|---|
| 50th percentile | IQR | 50th percentile | IQR | 50th percentile | 50th percentile | |
| Total Se (nmol/L) | 51.67 | (47.11–57.75) | 55.72 | (45.97–64.46) | 47.87 | 59.27 |
| Inorganic Se (nmol/L) | 7.98 | (5.83–9.50) | 8.49 | (5.45–10.13) | 7.47 | 9.50 |
| Se(IV) | 5.19 | (4.31–7.22) | 5.07 | (3.80–7.85) | 6.46 | 8.49 |
| Se(VI) | 1.52 | (1.14–3.93) | 2.91 | (1.65–4.31) | 1.01 | 1.01 |
| Organic Se (nmol/L) | 23.81 | (16.21–28.75) | 20.26 | (13.04–27.61) | 18.24 | 29.89 |
| Se-SelenoP | 20.64 | (15.20–25.84) | 18.36 | (11.90–23.18) | 16.34 | 26.72 |
| Se-Met | 1.65 | (1.01–2.79) | 1.90 | (0.89–2.91) | 1.39 | 3.17 |
| Se-Cys | 0.13 | (0.13–0.13) | 0.13 | (0.13–0.13) | 0.13 | 0.13 |
| Se-GPX | 0.13 | (0.13–1.14) | 0.13 | (0.13–0.76) | 0.51 | 0.13 |
| Se-HSA (nmol/L) | 17.73 | (14.69–22.67) | 20.90 | (14.69–23.30) | 17.22 | 16.08 |
| Unknown (nmol/L) | 3.17 | (1.77–4.56) | 3.55 | (2.03–5.95) | 1.90 | 4.18 |
| β-amyloid (pg/mL) | 699 | (521–963) | 506 | (417–519) | 761 | 611 |
| t-tau (pg/mL) | 256 | (198–404) | 625 | (404–743) | 222 | 355 |
| p-tau (pg/mL) | 60 | (46–85) | 86 | (73–128) | 47 | 67 |
AD Alzheimer’s dementia, β-amyloid Aβ1–42, FTD frontotemporal dementia, IQR interquartile range, LBD Lewy body dementia, MCI mild cognitive impairment, p-tau phosphorylated tau protein, Se selenium, Se(IV) selenite, Se(VI) selenate, Se-SelenoP selenoprotein P-bound Se, Se-Met selenomethionine-bound Se, Se-Cys selenocysteine-bound Se, Se-GPX glutathione-peroxidase-bound Se, Se-HSA human serum albumin selenium-bound Se, t-tau total tau protein